Genetic Ablation of KRAS in Pancreas Cancer: When an Essential Oncogene Isn’t

| January 5, 2018 | 0 Comments
Genetic Ablation of KRAS in Pancreas Cancer: When an Essential Oncogene Isn’t

Of all cancers, pancreatic cancers are most dependent on mutant KRAS. However, many pancreatic cancer cell lines survive loss of their mutant KRAS genes. The adaptations these lines make provide opportunities for treating these deadly cancers.
See Original Article

What Do We Mean By "RAS Pathway"?

Frank McCormick, scientific lead of the RAS Initiative, requests input from the RAS community to update our conception of the “RAS pathway”.
See Original Article

Program Spotlight: PACHE Partners Discuss Better Ways to Advance Cancer Health Equity

Program Spotlight: PACHE Partners Meet to Discuss Future of Program and Better Ways to Advance Cancer Health Equity
See Original Article

Category: Recent News

About the Author ()

Leave a Reply